Wuxi Pharmatech (WX) Reports In-Line Q2 EPS, Posts Q3 and FY11 Sales Guidance
Tweet
Share
E-mailGet Alerts WX Hot Sheet
Join SI Premium – FREE
Wuxi Pharmatech (NYSE: WX) reported Q2 EPS of $0.25, in-line with the analyst estimate of $0.25. Revenue for the quarter came in at $101.1 million versus the consensus estimate of $98.18 million.
Wuxi Pharmatech sees Q3 2011 revenue of $100-$103 million, versus the consensus of $101.17 million.
Wuxi Pharmatech sees FY2011 revenue of $400-$407 million, versus the consensus of $400.89 million.
Wuxi Pharmatech sees Q3 2011 revenue of $100-$103 million, versus the consensus of $101.17 million.
Wuxi Pharmatech sees FY2011 revenue of $400-$407 million, versus the consensus of $400.89 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
